AstraZeneca, Sanofi’s RSV therapy Beyfortus for infants shows ‘protection’ in trial Finances February 21, 2023 BeritK AstraZeneca (NASDAQ:AZN) and Sanofi’s (NASDAQ:SNY) antibody remedy Beyfortus continues to indicate constant safety towards Respiratory Syncytial Virus (RSV) illness…
Pfizer eyes $10B-plus market for RSV vaccines with pandemic-era model (NYSE:PFE) Markets August 28, 2022 Pfizer (NYSE:PFE) made a significant step ahead final week to entry a market alternative price greater than $10B for RSV…
